Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients

Tumor mutation load (TML) has been proposed as a biomarker of patient response to immunotherapy in several studies. TML is usually determined by tumor biopsy DNA (tDNA) whole exome sequencing (WES), therefore TML evaluation is limited by informative biopsy availability. Circulating cell free DNA (cf...

Descripción completa

Detalles Bibliográficos
Autores principales: Koeppel, Florence, Blanchard, Steven, Jovelet, Cécile, Genin, Bérengère, Marcaillou, Charles, Martin, Emmanuel, Rouleau, Etienne, Solary, Eric, Soria, Jean-Charles, André, Fabrice, Lacroix, Ludovic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697854/
https://www.ncbi.nlm.nih.gov/pubmed/29161279
http://dx.doi.org/10.1371/journal.pone.0188174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697854/
https://www.ncbi.nlm.nih.gov/pubmed/29161279
http://dx.doi.org/10.1371/journal.pone.0188174

Ejemplares similares